(Adnkronos) - In questo numero:
Malattie Rare, come cambia l’approccio all’Iap con terapia su misura e home delivery
Messa la prima pietra del Nuovo Gaslini di Genova, padiglione zero consegnato entro fine 2026
One Health, Il 59% degli italiani non sa cosa sia, la proposta di Amref contro le sfide della nostra epoca
A seguire Lo Speciale Salus Tv dal titolo: Autorizzata dall’Aifa la rimborsabilità del primo radioligando per il cancro della prostata metastatico resistente
Malattie Rare, come cambia l’approccio all’Iap con terapia su misura e home delivery
Messa la prima pietra del Nuovo Gaslini di Genova, padiglione zero consegnato entro fine 2026
One Health, Il 59% degli italiani non sa cosa sia, la proposta di Amref contro le sfide della nostra epoca
A seguire Lo Speciale Salus Tv dal titolo: Autorizzata dall’Aifa la rimborsabilità del primo radioligando per il cancro della prostata metastatico resistente
Category
🗞
NewsTranscript
00:00In this issue, rare diseases, how the approach to IAPA changes with tailor-made therapy and home delivery.
00:18Put the first stone of the new Gaslini of Genoa, Padiglione Zero, delivered by the end of 2026.
00:25One Health, the 59% of Italians do not know what is, the proposal of Amref against the challenges of our time.
00:34To follow the special Salus TV from the title, authorized by the IFA, the reimbursability of the first radioligand for the cancer of the metastatic resistant prostate.
00:49Dizziness, fatigue and fainting are the main symptoms of pulmonary arteriosclerosis, a rare and serious pathology that affects small-caliber blood vessels of the lungs.
01:00In Italy there are about 3,000 people with a higher incidence in the population between 30 and 60 years, a period of life in which people are particularly active,
01:11which makes the diagnosis more complex because the first symptoms are often underestimated.
01:17Pulmonary arteriosclerosis is a rare disease that is characterized by the obstruction of the small pulmonary arteries,
01:23which progressively involve the resistance of the pulmonary circle and therefore the right ventricle, which pumps the blood inside the lung,
01:33goes against a dilatation, a serious dysfunction, therefore it is among the most serious and severe forms of heart failure that we know.
01:42Reaching the pharmacies of the hospital centers, often located far from home, is a burden for patients affected by pulmonary arteriosclerosis,
01:50which adds to the overall weight of disease management.
01:53In this context, the scientific and organizational innovation of IOP Health, a global pioneer in integrated therapies for rare diseases and intensive therapy,
02:03provides a home delivery service that allows patients to receive the drug at home,
02:08facilitating therapeutic continuity, reducing logistical stress and improving their quality of life.
02:14For patients affected by this disease, there is already a home H24 nursing service,
02:23and this is essential because the patient in this way feels safe when the infusion site changes, when the needle changes.
02:32From today, home delivery is added to this important step, because these drugs are not found in pharmacies,
02:39but must be taken to the hospital.
02:42Home delivery is therefore a further step forward towards a lower organizational and logistical load for the patient,
02:49better adherence to therapy and, in the last analysis, an improvement in quality of life.
02:54The first stone was laid for the construction of the new Gaslini Hospital in Genoa,
03:03the first important step in the restructuring of the national and European hospitality excellence in pediatric care.
03:10The President of the Liguria Region, Marco Bucci, the Deputy Secretary of Health, Marcello Gemmato,
03:21the Deputy Minister of Infrastructure and Transport, Edoardo Rixi, and the Deputy Mayor of the City of Genoa, Pietro Picciocchi.
03:28At Padiglione Zero, whose delivery is scheduled for the end of 2026, Padiglioni 1 and 2 will follow.
03:35The conclusion of the work is scheduled for 2029.
03:39The first stone of the first pavilion, which we call Padiglione Zero, on which the works are already underway,
03:48is a historic moment because it will mark, with the completion of the work, probably the role of Gaslini in the next century.
03:57It is therefore essential to continue to be excellent for a modern medicine, which has changed a lot in many years,
04:08which needs very different physical and technological structures compared to those of the past
04:14and which is placed as a major pediatric clinical and scientific challenge internationally.
04:23We host children from 40 countries around the world as small patients,
04:31and we must be able to be up to this level of competence also for the future.
04:36And this is the meaning of this day.
04:39In facing this operation, the Gaslini Institute had courage.
04:43Both in doing it here, in the historic headquarters, because it is much easier to build a new hospital in another headquarters
04:50and then move at the same time, than not to work in the same hospital and try to maintain the activities as we are doing.
04:58The other element of courage, I think, is the tool.
05:02We have adopted a grant, a private public partnership, which is a very interesting tool,
05:10but which obviously requires knowledge and skills,
05:14and also a very important collaboration with the actors who are helping us,
05:17therefore the CMB concessionaire, the cooperative Muratori e Braccianti di Carpi,
05:22with the support of IRINA, which also helps us in the activities of project management and work direction.
05:27The engineering project for the new Gaslini is particularly complex
05:32and required the creation of a very detailed digital twin.
05:36It is complex because we are in the middle of the city,
05:40with the buildings very close, the buildings of our neighbors and the same hospital,
05:47which must continue to function during this construction.
05:51So already starting from the demolition phase,
05:54we had to use demolition techniques that are not the most common,
05:59but they are real deconstructions of the building.
06:02And now that we will go down to the excavation and foundation phases,
06:07we must always maintain a high level of attention and monitoring of the surrounding environment
06:14in relation to the production of dust, vibrations,
06:18especially to allow the rest of the hospital to continue to function
06:23and to guarantee safe care for our small patients.
06:27Demographic growth, progressive loss of biodiversity,
06:32climate change and the emergence of new infectious diseases.
06:37It is now known that these are the four main challenges of our time
06:41and to be able to face them, new approaches and innovative intervention strategies are necessary,
06:45such as the One Health promoted by AMREF, which integrates different aspects,
06:49human health, environmental health and animal health.
06:52Most of the problems, in fact, originate in the human-animal-environment interface
06:56and in the same interface that it is possible to find solutions.
06:59No scientific discipline and no country, however,
07:02has the knowledge and sufficient resources to face the emerging health problems individually.
07:07However, based on what has been documented by the African Health Survey and the opinion of the Italians,
07:11carried out by Ipsos by AMREF Italy,
07:14well 59% of Italians have never heard of it,
07:17and this especially among the older generations, boomers and Generation X.
07:21Despite the lack of knowledge, however, once presented the founding principles of One Health,
07:2573% of the entire population considers it convincing.
07:28It is therefore necessary to emphasize to AMREF an investment and a collective effort
07:32to develop the knowledge and skills necessary.
07:35And as Roberto Arruetti, director of the AMREF Italy programs,
07:39supports, One Health proposes precisely this,
07:41a collaborative approach between different professional disciplines
07:44to achieve an optimal and integrated health condition of people, animals and the environment.
07:49We at AMREF One Health have been working on it since 2015,
07:53since we have been promoting One Health programs in Africa,
07:57and in particular in East Africa, in the Horn of Africa,
08:00the region most affected by climate change.
08:04In our projects we promote One Health Units,
08:08units where it is possible to have access to animal health services,
08:13human health services and environmental protection.
08:16We work in close contact with local authorities and communities.
08:20Community observation networks are essential.
08:23They help us to monitor the climate conditions,
08:27but also the health conditions of animals
08:29and to intervene in a timely manner when there is a crisis.
08:32This is to reduce the impacts of a potential crisis,
08:36both on the well-being of communities, but also on their ability to produce income.
08:41Therefore, One Health is an effective approach
08:44capable of facing the challenges of our time.
08:47It must be supported through a political will
08:51and through adequate economic resources.
08:59The precision therapy based on the use of lutezium,
09:04the first radioligand for patients with metastatic prostatic tumor
09:08resistant to castration, positive for PSMA,
09:11the specific membrane antigen of the prostate.
09:14Thanks to the approval and reimbursement by the CDA of the IFA
09:18to the Italian Pharmaceutical Agency,
09:20the innovative treatment will be available for patients with this type of neoplasia
09:24not responding to the therapies already available,
09:27it is hoped, from mid-March.
09:29The new target marks a significant evolution
09:32in the treatment of a complex oncological pathology
09:36expanding the available therapeutic options and improving survival.
09:40Moreover, prostatic carcinoma is the most common tumor among men in Western countries
09:46and in Italy it represents 29.9% of all male tumors.
09:50There are 485,000 people who live with this oncological diagnosis
09:55and 40,192 new cases only in 2024.
10:00The metastatic form resistant to castration
10:03is the most advanced phase of the disease,
10:05with an average survival of 5 years that does not exceed 30%.
10:09The PSMA receptor is present in more than 80% of patients with metastatic disease.
10:16But what does the therapy with radioligands consist of in simple words?
10:20We asked Professor Carmine Pinto,
10:23Director of Medical Oncology of the Comprehensive Cancer Center
10:27of the local health unit IRCS of Reggio Emilia.
10:31We are in a new and relevant phase in the treatment of tumors.
10:36We always try to have more treatments that individualize a target
10:41and to have the drug or in the specific case of radiation
10:45that can directly hit that target and therefore hit the neoplastic cell.
10:50And in this case, how does the one that in nuclear medicine is defined as teragnostic come from?
10:55Where does it start?
10:57We have a carrier to which a radioisotope is linked
11:00that through this carrier finds cellular alterations within the tumor cells
11:05and is used in the diagnostic phase as a tracer,
11:09where are these altered cells that capture this radioisotope
11:13and therefore become positive.
11:15This is the first phase.
11:17To this carrier, however, we can also link a radioisotope,
11:20this is the teragnostic, which can have a therapeutic function.
11:24So I can link to the carrier at this point a radioisotope with a therapeutic function
11:29and hit that single target within that cell
11:34and therefore have a targeted radiotherapy
11:37that hits exactly where I want to hit.
11:41And what advantages do you get with this therapeutic approach?
11:44I can give a high dose of irritation,
11:47I try to reduce the side effects as much as possible,
11:50but above all I can go and evaluate over time if my PET turns off,
11:55if that treatment was effective or not.
11:58This is called teragnostics and it is the great future,
12:01in my opinion, of personalized nuclear medicine.
12:04And in practice, how will this approach change the management of the disease?
12:08Dr. Giuseppe Procompio,
12:10responsible for medical oncology, genitourinary,
12:13explains it to us at the IRCS Foundation,
12:15the National Institute of Tumors in Milan.
12:17Radioligand therapy sees the access and the preeminent entry of teragnostics
12:23in prostate carcinoma.
12:25It means that we identify targets through a diagnostic,
12:30a sophisticated imaging,
12:32and on these targets we define a targeted and personalized cure path,
12:38which is based on the use of radioisotopes
12:41that act on membrane antigens
12:44that are expressed on the surface of the prostate tumor cells.
12:49But what benefits does this therapy give in particular?
12:52To use a different action mechanism.
12:54The advantage is to use a precision medicine.
12:57For the patient, the advantage is the anti-tumor effectiveness
13:01already demonstrated and validated in multiple clinical studies.
13:05In this regard, the results of the Phase III study, VISION,
13:08are particularly significant.
13:11The VISION study has shown that in a population
13:14that had received a previous androgenic deprivation,
13:18including also new generation anti-androgens,
13:22that had received a previous chemotherapy,
13:25the use of lutezium was able to slow the progression of the disease,
13:30to improve the life expectancy,
13:33to improve the control of symptoms and the quality of life.
13:37So an impact on what are the most significant clinical objectives
13:41for the life of our patients.
13:43So the arrival of lutezium will be a sensible step forward
13:48in the attempt to chronicle the advanced oncological disease.
13:52An innovation, the one we talked about,
13:55which has its roots in the Made in Italy research carried out by VREA,
13:59actually at the forefront of the Novartis group,
14:01which developed the first therapies with radiopharmaceuticals.
14:04And the Swiss multinational company,
14:06which has been committed for over 20 years
14:08in the development of innovative pharmaceuticals
14:10and new technological platforms,
14:12is very satisfied, as underlines Paola Cocco,
14:15Medical Affairs Head of Novartis,
14:17for the agreement signed with AIFA,
14:19which will allow patients and the National Health Service
14:22to have access to this important therapeutic novelty in a sustainable way.
14:27Today we are very, very proud of this result
14:31that we have obtained thanks to an incessant collaboration
14:36with regulatory authorities,
14:38which will finally be able to offer patients
14:42affected by prostate carcinoma resistant to castration
14:47a new therapeutic opportunity
14:49able to extend the life expectancy
14:53maintaining and preserving as much as possible a good quality of life.
15:04This was our latest news.
15:06To contact us you can write to salute-adnkronos.com
15:10Thank you for following us and see you next time.